The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

• Status: Completed
• Trial end date: 1998-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the steady state pharmacokinetic features, tolerance, and safety of orally administered 1592U89, given alone or in combination with other antiretroviral medications, in HIV infected infants and children. To establish doses of 1592U89 appropriate for future pediatric Phase II/III clinical trials.

On the basis of the preclinical and clinical studies, 1592U89 appears to be a promising agent for treatment of HIV infection in children, either as an alternative to currently employed agents, or in combination therapy regimens. A liquid formulation of the drug is available; thus concurrent development of 1592U89 for children and adults is possible.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Abacavir; Anti-Retroviral Agents; Didanosine; Lamivudine; Stavudine; Zidovudine

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• IVIG.

• Erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor (for management of hematologic toxicity).

Patients must have:

• Documented HIV-1 infection.

• Laboratory evidence of immunosuppression or symptomatic HIV disease.

• Parent or legal guardian able and willing to provide signed informed consent.

Prior Medication: Required:

• HIV infected infants and children will be eligible for the trial if they have received greater than 56 days of previous antiretroviral therapy.

NOTE:

• Those children who participated in the single dose phase I study of 1592U89 and satisfy all other criteria for inclusion may have received <= 56 days of previous antiretroviral therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

• Grade 3 or greater abnormalities in any toxicity monitoring laboratory tests at baseline.

• Presence of an acute opportunistic infection requiring therapy at the time of enrollment.

• Intractable or chronic diarrhea or vomiting.

Concurrent Medication:

Excluded:

• Chemotherapy for active malignancy.

• Concurrent use of antiretroviral agents other than those provided by the study, biologic response modifiers, human growth hormone, systemic corticosteroids (>= 14 days duration), probenecid, I.V. pentamidine, immunomodulators (other than intravenous immunoglobulin), or other investigational drugs.

Patients with any of the following prior conditions or symptoms are excluded:

• History of intolerance to any of the study drugs.